Trials / Withdrawn
WithdrawnNCT02662894
Fixed-dose Combination of Valsartan + Rosuvastatin Versus Their Isolated Components for Hypertension and Dyslipidemia.
Efficacy of Fixed-dose Combination of Valsartan + Rosuvastatin Versus Their Isolated Components for Hypertension and Dyslipidemia.
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- EMS · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Noninferiority trial to assess efficacy of fixed-dose combination of valsartan + rosuvastatin versus their isolated components in treatment of hypertension and dyslipidemia.
Detailed description
* Open-label,randomized, multicenter; * Maximal experiment duration: 8 weeks; * 04 visits; * Safety and efficacy evaluation
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Valsartan 160mg + Rosuvastatin 20mg | 1 tablet, oral, a day |
| DRUG | Valsartan 320mg + Rosuvastatin 20mg | 1 tablet, oral, a day |
| DRUG | Diovan® 160mg + Crestor® 20mg | Take together 1 tablet of Diovan (160mg) plus 1 tablet of Crestor (20mg), oral, once daily. |
| DRUG | Diovan® 320mg + Crestor® 20mg | Take together 1 tablet of Diovan (320mg) plus 1 tablet of Crestor (20mg), oral, once daily. |
Timeline
- Start date
- 2019-10-01
- Primary completion
- 2020-09-01
- Completion
- 2020-12-01
- First posted
- 2016-01-26
- Last updated
- 2021-02-24
Source: ClinicalTrials.gov record NCT02662894. Inclusion in this directory is not an endorsement.